The Cancer

Don't Miss

Childhood Most cancers Survivors Face Lengthy-Time period Meningioma Danger

Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...

Professional Discusses FDA Approval of Chemo-Free Possibility for EGFR-Mutated Lung Most cancers

The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...

FDA Clears Protocol Replace for Tasquinimod in Myelofibrosis Trial

Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...

Vital Information

Facts

Latest Articles

Lymphoma Survivors Discover Fatigue Aid From Multidisciplinary Intervention

Lymphoma survivors with persistent fatigue taking part in a multidisciplinary intervention program skilled a useful impact on fatigue and on some elements...

Keytruda Combo Improves Development, Survival in Recurrent Ovarian Most cancers

Amongst sufferers with platinum-resistant recurrent ovarian most cancers (PRROC), the remedy mixture of Keytruda (pembrolizumab) with weekly paclitaxel with or with out...

Imdelltra Improves Survival For Some With Small Cell Lung Most cancers

Amongst sufferers with small cell lung most cancers (SCLC), therapy with Imdelltra (tarlatamab-dlle) was discovered to enhance general survival (OS) in comparison...

Youthful Feminine Sufferers With Most cancers Report Much less Emotional Operate

Amongst sufferers with strong tumors, evaluation of patient-reported outcomes for emotional functioning (EF) confirmed that at baseline EF was average, and it...

Imdelltra Plus Chemoimmunotherapy Safely Elicits Responses in ES-SCLC

Amongst sufferers with extensive-stage (ES) small cell lung most cancers (SCLC), therapy with Imdelltra (tarlatamab) plus frontline chemotherapy and PD-L1 upkeep remedy...

Hot Topics